Thryv Therapeutics Secures FDA Orphan Drug Designation for LQT-1213 to Treat Long QT Syndrome

Thryv Therapeutics, a clinical stage biotech company dedicated to developing treatments for rare and life-threatening cardiovascular indications, announced...

October 02, 2024 | Wednesday | News
Alora Pharmaceuticals Champions ADHD Awareness Month: Empowering the ADHD Community

This ADHD Awareness Month, we stand with the ADHD community. Alora Pharmaceuticals, LLC, the largest U.S. manufacturer of methylphenidate medications,...

October 02, 2024 | Wednesday | News
Thermo Fisher Scientific Launches Global Adolescent Atopic Dermatitis Registry to Advance Treatment Research

Thermo Fisher Scientific Inc., the world leader in serving science, announced the launch of the international CorEvitas Adolescent Atopic Dermatitis (AD)...

October 01, 2024 | Tuesday | News
IASO Biotherapeutics and Chinese Experts Explore Collaboration with Brazil on Cutting-Edge Cancer Therapies

On the eve of the International Myeloma Society (IMS) Annual Meeting, Dr. Yongke Zhang, Chief Scientific Officer of IASO Biotherapeutics (IASO Bio), along ...

September 30, 2024 | Monday | News
SIFI Secures European Patent for Innovative Polihexanide Formulation in Germany Eye Infection Treatment

The company's intellectual property ("IP") covers the formulation and method of use of polihexanide in the treatment of acanthamoeba keratitis and fung...

September 30, 2024 | Monday | News
Phase 3 CEPHEUS Study Shows 60.9% MRD-Negativity Rate and 43% Reduction in Risk of Progression or Death in Multiple Myeloma

Study demonstrates a minimal residual disease (MRD)-negativity rate of 60.9 percent and 43 percent reduction in the risk of progression or death1 Phase ...

September 30, 2024 | Monday | News
Enliven Therapeutics Reports Promising 44% MMR Rate at 24 Weeks in Phase 1 CML Trial for ELVN-001

Reported cumulative MMR rate of 44% by 24 weeks, with stable or deepening responses between weeks 12 and 24, continuing to surpass prior Phase 1 trials o...

September 30, 2024 | Monday | News
Takara Bio Europe Launches Shasta™ Single-Cell System, Advancing High-Throughput Oncology Biomarker Discovery

Takara Bio Europe, a wholly owned subsidiary of Takara Bio Inc., announces the launch of the Shasta™ Single-Cell System at the 2024 Human Cell A...

September 27, 2024 | Friday | News
Thermo Fisher Scientific Expands OSD Capabilities with $22 Million Investment to Accelerate Drug Development

To provide flexible and innovative solutions for early development challenges commonly faced by biotech and pharmaceutical companies, Thermo Fisher Scien...

September 27, 2024 | Friday | News
Emmes Secures Major NIH Contract to Lead Clinical Coordinating Center for National Institute on Drug Abuse Trials

Emmes, part of Emmes Group, announced they will provide a Clinical Coordinating Center for the NIH's National Institute on Drug Abuse Clinical Trials &nbs...

September 26, 2024 | Thursday | News
Eli Lilly CEO David Ricks Announces Major Expansion of India Research Hub, Poised to Transform Global Drug Innovation

Eli Lilly and Company (NYSE: LLY), a global leader in biopharmaceuticals, has announced plans to expand its research and development (R&D) center in ...

September 24, 2024 | Tuesday | News
Nxera Pharma Secures Japanese Approval for QUVIVIQ™ to Treat Insomnia Based on Positive Phase 3 Trial Results

The approval of QUVIVIQ™, a novel dual orexin receptor antagonist, is based on robust clinical efficacy and safety data, including from a Phase 3...

September 24, 2024 | Tuesday | News
Thermo Fisher's PPD Clinical Research Expands to GoCo Health Innovation City in Sweden

The PPD clinical research business joins GoCo Health Innovation City in Gothenburg, Sweden The PPD™ clinical research business of Thermo Fisher Sc...

September 19, 2024 | Thursday | News
Vidac Pharma Secures Broad U.S. Patent for Pioneering Cancer Treatment Mode of Action

Vidac Pharma Holdings Plc., a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments,  announces that the U...

September 19, 2024 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close